Lind Global’s capped stake in Dare Bioscience (NASDAQ: DARE) tops key ownership threshold

Rhea-AI Filing Summary

Dare Bioscience, Inc. (DARE) reports that Lind Global Fund III LP, Lind Global Partners III LLC, and Jeff Easton have jointly filed as significant shareholders on a Schedule 13G. Each reporting person is deemed to beneficially own 1,094,890 shares of common stock, representing 5.65% of the outstanding common stock, with sole voting and dispositive power over these shares.

The ownership position is structured as (i) 1,094,890 common shares, (ii) 1,094,890 Series A Warrants, and (iii) 1,094,890 Series B Warrants. A 4.99% beneficial ownership limitation in the warrants caps how many shares can be owned through conversion at any time, so aggregate beneficial ownership is limited to 1,094,890 shares.

Key Figures

Beneficially owned common shares: 1,094,890 shares Percent of class: 5.65% Series A Warrants: 1,094,890 warrants +2 more

5 metrics

Beneficially owned common shares 1,094,890 shares Shares of Dare Bioscience, Inc. common stock reported as beneficially owned by each reporting person

Percent of class 5.65% Percentage of Dare Bioscience, Inc. outstanding common stock beneficially owned by each reporting person

Series A Warrants 1,094,890 warrants Warrants to purchase Dare Bioscience common stock held by each reporting person

Series B Warrants 1,094,890 warrants Additional warrants to purchase Dare Bioscience common stock held by each reporting person

Beneficial ownership limitation 4.99% Warrant provision preventing conversions that would result in ownership above this threshold

Key Terms

beneficial ownership, dispositive power, Schedule 13G, conversion limitations, +1 more

5 terms

beneficial ownership financial

"the reporting person's beneficial ownership has been limited to 1,094,890 shares in the aggregate"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

dispositive power financial

"Sole Dispositive Power 1,094,890.00 8 | Shared Dispositive Power 0.00"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

Schedule 13G regulatory

"This statement is filed by the following entities and individuals ... as the "Reporting Persons""

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

conversion limitations financial

"however, due to the conversion limitations on the Warrants, the reporting person's beneficial ownership"

beneficial ownership limitation financial

"The Warrants include a provision limiting the holder's ability to convert the Warrants"

A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.

FAQ

What percentage of Dare Bioscience (DARE) does Lind Global Fund III report owning?

Lind Global Fund III LP, together with Lind Global Partners III LLC and Jeff Easton, reports beneficial ownership of 5.65% of Dare Bioscience’s common stock, based on 1,094,890 shares over which they have sole voting and dispositive power.

How many Dare Bioscience (DARE) shares does Lind Global report beneficially owning?

The reporting persons collectively report beneficial ownership of 1,094,890 shares of common stock of Dare Bioscience, Inc. This amount reflects the impact of a beneficial ownership limitation contained in their warrants.

What securities of Dare Bioscience (DARE) are held by the Lind Global reporting group?

The reporting persons’ position consists of (i) 1,094,890 common shares, (ii) 1,094,890 Series A Warrants, and (iii) 1,094,890 Series B Warrants of Dare Bioscience, Inc., subject to a conversion limitation capping beneficial ownership.

What is the beneficial ownership limitation in the Dare Bioscience (DARE) warrants?

The Series A and Series B Warrants held by the reporting persons include a provision that limits conversion if it would cause the holder to beneficially own more than 4.99% of Dare Bioscience’s outstanding common stock, effectively capping exercisable ownership at that level.

Who are the reporting persons in this Dare Bioscience (DARE) Schedule 13G filing?

The Schedule 13G is filed by Lind Global Fund III LP, Lind Global Partners III LLC, and Jeff Easton. Lind Global Partners III LLC is the general partner of Lind Global Fund III LP, and Jeff Easton is the managing member of Lind Global Partners III LLC.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/28/2026 - 04:01 PM Accepted by SEC EDGAR 08/28/2026 - 04:00 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Dare Bioscience, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value

(Title of Class of Securities)

23666P200

(CUSIP Number)

08/17/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 23666P200

1

Names of Reporting Persons

Lind Global Fund III LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,094,890.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,094,890.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,094,890.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.65 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: (1) The reporting person's ownership consists of (i) 1,094,890 shares of common stock, (ii) 1,094,890 warrants to purchase shares of common stock (the "Series A Warrants"), and (iii) 1,094,890 warrants to purchase shares of common stock (the "Series B Warrants," together with the Series A Warrants, the "Warrants"); however, due to the conversion limitations on the Warrants, the reporting person's beneficial ownership has been limited to 1,094,890 shares in the aggregate. (2) The Warrants include a provision limiting the holder's ability to convert the Warrants if such conversion would cause the holder to beneficially own greater than 4.99% of the Company.

SCHEDULE 13G

CUSIP Number(s): 23666P200

1

Names of Reporting Persons

Lind Global Partners III LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,094,890.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,094,890.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,094,890.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.65 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: (1) The reporting person's ownership consists of (i) 1,094,890 shares of common stock, (ii) 1,094,890 Series A Warrants, and (iii) 1,094,890 Series B Warrants; however, due to the conversion limitations on the Warrants, the reporting person's beneficial ownership has been limited to 1,094,890 shares in the aggregate. (2) The Warrants include a provision limiting the holder's ability to convert the Warrants if such conversion would cause the holder to beneficially own greater than 4.99% of the Company.

SCHEDULE 13G

CUSIP Number(s): 23666P200

1

Names of Reporting Persons

EASTON JEFF

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,094,890.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,094,890.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,094,890.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.65 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: (1) The reporting person's ownership consists of (i) 1,094,890 shares of common stock, (ii) 1,094,890 Series A Warrants, and (iii) 1,094,890 Series B Warrants; however, due to the conversion limitations on the Warrants, the reporting person's beneficial ownership has been limited to 1,094,890 shares in the aggregate. (2) The Warrants include a provision limiting the holder's ability to convert the Warrants if such conversion would cause the holder to beneficially own greater than 4.99% of the Company.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Dare Bioscience, Inc.
(b)	Address of issuer's principal executive offices: 3655 Nobel Drive, Suite 260, San Diego, California, 92122
Item 2.
(a)	Name of person filing: This statement is filed by the following entities and individuals (collectively, referred to as the "Reporting Persons"): Lind Global Fund III LP, a Delaware limited partnership; Lind Global Partners III LLC, a Delaware limited liability company; and Jeff Easton, an individual and a citizen of the United States of America. Lind Global Partners III LLC, the general partner of Lind Global Fund III LP, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund III LP. Jeff Easton, the managing member of Lind Global Partners III LLC, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund III LP.
(b)	Address or principal business office or, if none, residence: The address of the principal business office for each of the Reporting Persons is: 444 Madison Ave, Floor 41 New York, NY 10022
(c)	Citizenship: See Row 4 of cover page for each Reporting Person.
(d)	Title of class of securities: Common Stock, $0.0001 par value
(e)	CUSIP Number(s): 23666P200
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See Row 9 of cover page for each Reporting Person.
(b)	Percent of class: See Row 11 of cover page for each Reporting Person.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See Row 5 of cover page for each Reporting Person.
	(ii) Shared power to vote or to direct the vote: See Row 6 of cover page for each Reporting Person.
	(iii) Sole power to dispose or to direct the disposition of: See Row 7 of cover page for each Reporting Person.
	(iv) Shared power to dispose or to direct the disposition of: See Row 8 of cover page for each Reporting Person.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Lind Global Fund III LP

Signature:	Lind Global Partners III LLC, its General Partner
Name/Title:	Jeff Easton, Managing Member
Date:	08/28/2026

Lind Global Partners III LLC

Signature:	Lind Global Partners III LLC
Name/Title:	Jeff Easton, Managing Member
Date:	08/28/2026

EASTON JEFF

Signature:	Jeff Easton
Name/Title:	Jeff Easton, Managing Member
Date:	08/28/2026

Exhibit Information

Exhibit 99.1 - Joint Filing Agreement